Salt forms of (S)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate
AssigneeGenzyme Corporation
InventorsCraig S. Siegel, Jin Zhao
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel salt forms of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate useful as an inhibitor of glucosylceramide synthase (GCS) and for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
Claims24
A crystalline Form A of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate malate, wherein said x-ray powder diffraction contains the following 2-theta peak measured using CuKα radiation:
- 18.095.
A crystalline Form A of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate malate, wherein said x-ray powder diffraction contains the following 2-theta peaks measured using CuKα radiation:
- 18.095 and 17.493.
A crystalline Form A of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate malate, wherein said x-ray powder diffraction contains the following 2-theta peaks measured using CuKα radiation:
- 18.095 and 19.516.
A crystalline Form A of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate malate, wherein said x-ray powder diffraction contains the following 2-theta peaks measured using CuKα radiation:
- 18.095, 17.493, and 19.516.
A crystalline Form A of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate malate, wherein said x-ray powder diffraction contains the following 2-theta peaks measured using CuKα radiation:
- 18.095, 17.493, 19.516 and 20.088.
A crystalline Form A of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate malate, wherein said x-ray powder diffraction contains the following 2-theta peaks measured using CuKα radiation:
- 18.095, 17.493, 19.516 and 20.088 and 17.125.
A crystalline Form B of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate malate, wherein said x-ray powder diffraction contains the following 2-theta peak measured using CuKα radiation:
- 24.355.
A crystalline Form B of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate malate, wherein said x-ray powder diffraction contains the following 2-theta peaks measured using CuKα radiation:
- 24.355 and 21.167.
A crystalline Form B of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate malate, wherein said x-ray powder diffraction contains the following 2-theta peaks measured using CuKα radiation:
- 24.355, 21.167 and 27.343.
A crystalline Form B of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate malate, wherein said x-ray powder diffraction contains the following 2-theta peaks measured using CuKα radiation:
- 24.355, 21.167, 27.343 and 16.111.
A crystalline Form B of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate malate, wherein said x-ray powder diffraction contains the following 2-theta peaks measured using CuKα radiation:
- 24.355, 21.167, 27.343, 16.111 and 17.185.
A crystalline Form B of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate malate, wherein said x-ray powder diffraction contains the following 2-theta peaks measured using CuKα radiation:
- 24.355, 21.167, 27.343, 16.111, 17.185 and 20.243.
A crystalline form of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate (S)-2-hydroxysuccinate salt, wherein said x-ray powder diffraction contains the following 2-theta peak measured using CuKα radiation:
- 17.162.
A crystalline Form A of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate (S)-2-hydroxysuccinate salt, wherein said x-ray powder diffraction contains the following 2-theta peaks measured using CuKα radiation:
- 17.162 and 18.028.
A crystalline form of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate (S)-2-hydroxysuccinate salt, wherein said x-ray powder diffraction contains the following 2-theta peaks measured using CuKα radiation:
- 17.162 and 14.280.
A crystalline form of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate (S)-2-hydroxysuccinate salt, wherein said x-ray powder diffraction contains the following 2-theta peaks measured using CuKα radiation:
- 17.162, 18.028 and 14.280.
A crystalline form of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate (S)-2-hydroxysuccinate salt, wherein said x-ray powder diffraction contains the following 2-theta peaks measured using CuKα radiation:
- 17.162, 18.028, 14.280 and 18.153.
A crystalline form of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate (S)-2-hydroxysuccinate salt, wherein said x-ray powder diffraction contains the following 2-theta peaks measured using CuKα radiation:
- 17.162, 18.028, 14.280, 18.153 and 23.422.
A crystalline form of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate HCl salt, wherein said x-ray powder diffraction contains the following 2-theta peak measured using CuKα radiation:
- 18.087.
A crystalline form of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate HCl salt, wherein said x-ray powder diffraction contains the following 2-theta peak measured using CuKα radiation:
- 12.818.
A crystalline form of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate HCl salt, wherein said x-ray powder diffraction contains the following 2-theta peak measured using CuKα radiation:
- 25.722.
A crystalline form of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate HCl salt, wherein said x-ray powder diffraction contains the following 2-theta peaks measured using CuKα radiation:
- 12.818 and 25.722.
A crystalline form of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate HCl salt, wherein said x-ray powder diffraction contains the following 2-theta peaks measured using CuKα radiation:
- 12.818, 25.722 and 13.040.
A crystalline form of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate HCl salt, wherein said x-ray powder diffraction contains the following 2-theta peaks measured using CuKα radiation:
- 12.818, 25.722, 13.040 and 28.910.
Dependencies are inferred from the claim text.